{"id":"W4385644723","doi":"10.1097/01.hs9.0000967696.13096.54","title":"S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Refractory (planetary science); Adverse effect; Gastroenterology; Multiple myeloma; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005676261,0.0002876681,0.0005645829,0.000165169,0.0002357532,0.0003157378,0.0003426049,0.0003372749,0.005269056],"category_scores_gemma":[0.0003342534,0.0001112329,0.0004986678,0.0002388148,0.0001738794,0.0002684995,0.000195574,0.0005884593,0.0008970321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005630908,"about_ca_system_score_gemma":0.0006442392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005976987,"about_ca_topic_score_gemma":0.001654731,"domain_scores_codex":[0.9998608,0.00005110559,0.00001245795,0.00002430458,0.00002315977,0.00002821145],"domain_scores_gemma":[0.9998146,0.00003124932,0.00005652114,0.00001226735,0.00001332596,0.00007207879],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.295438,0.007261954,0.09265249,0.001231552,0.001183982,0.00176607,0.0002165042,0.002141465,0.0955586,0.0003002553,0.01523795,0.4870111],"study_design_scores_gemma":[0.2906412,0.2573363,0.3612282,0.0002221121,0.001635508,0.005077405,0.0001200455,0.005373801,0.03227019,0.000477241,0.04555302,0.00006497036],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991583,0.002346819,0.0004800992,0.0005491285,0.00007042428,0.0004967529,0.001525078,0.00008166625,0.00286693],"genre_scores_gemma":[0.9932867,0.0006341347,0.0008222255,0.0004851836,0.0001208957,0.000263025,0.002580839,0.00001394318,0.001793106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005269056,"threshold_uncertainty_score":0.0176267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01863870885240338,"score_gpt":0.2789849677210768,"score_spread":0.2603462588686734,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}